मूलभूत आँकड़े
| CIK | 1226616 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MediciNova, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 22, 2025 |
As filed with the Securities and Exchange Commission on August 22, 2025 S-1 Table of Contents As filed with the Securities and Exchange Commission on August 22, 2025 Registration No. |
|
| August 22, 2025 |
Calculation of Filing Fee Tables S-1 MEDICINOVA INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-33185 MEDICINOVA, INC. |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2025 MEDICINOVA, INC. |
|
| August 1, 2025 |
EX-10.1 Exhibit 10.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of July 30, 2025 is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and MEDICINOVA, INC, a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to herein individu |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-33185 MEDICINOVA, INC. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 11, 2025 |
Exhibit 99.1 MediciNova Corporate Presentation March 2025 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding MediciNova’s clinical trials supporting the |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 11, 2025 MEDICINOVA, INC. (Exact name of registrant as specified in charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 19, 2025 |
Exhibit 19.1 MEDICINOVA, INC. Statement of Company Policy Trades in the Company’s Securities by Insiders (Company Personnel, Board Members and designated Consultants, Advisors and Contractors to the Company) and Confidential Information 1. Purpose. Both the Securities and Exchange Commission (the “SEC”) and Congress are concerned about maintaining the fairness of the U.S. securities markets, and t |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33185 MEDICINOVA, INC. |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-33185 MEDICINOVA, INC. |
|
| August 8, 2024 |
CONSULTING AGREEMENT Effective April 2, 2024 (the “Effective Date”), Geoffrey O’Brien (“Consultant”) and MEDICINOVA, INC. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| June 12, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from. |
|
| February 15, 2024 |
Exhibit 19.1 MEDICINOVA, INC. Statement of Company Policy Trades in the Company’s Securities by Insiders (Company Personnel, Board Members and designated Consultants, Advisors and Contractors to the Company) and Confidential Information 1. Purpose. Both the Securities and Exchange Commission (the “SEC”) and Congress are concerned about maintaining the fairness of the U.S. securities markets, and t |
|
| February 15, 2024 |
MediciNova, Inc. Recovery of Erroneously Awarded Compensation Policy. Exhibit 97.1 MEDICINOVA, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1. Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the S |
|
| January 19, 2024 |
EX-99.1 Exhibit 99.1 MEDICINOVA, INC. 2023 EQUITY INCENTIVE PLAN MEDICINOVA, INC. 2023 EQUITY INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Board adopted the Plan on April 26, 2023, subject to the approval of the Company’s stockholders. No Awards may be granted prior to the Effective Date. The Plan replaces the Company’s 2013 Equity Incentive Plan (the “Predecessor Plan”) for awards granted on or af |
|
| January 19, 2024 |
As filed with the Securities and Exchange Commission on January 19, 2024 S-8 POS As filed with the Securities and Exchange Commission on January 19, 2024 Registration No. |
|
| January 19, 2024 |
As filed with the Securities and Exchange Commission on January 19, 2024 S-8 POS As filed with the Securities and Exchange Commission on January 19, 2024 Registration No. |
|
| January 19, 2024 |
2023 Equity Incentive Plan and forms of award agreements thereunder. EX-99.1 Exhibit 99.1 MEDICINOVA, INC. 2023 EQUITY INCENTIVE PLAN MEDICINOVA, INC. 2023 EQUITY INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Board adopted the Plan on April 26, 2023, subject to the approval of the Company’s stockholders. No Awards may be granted prior to the Effective Date. The Plan replaces the Company’s 2013 Equity Incentive Plan (the “Predecessor Plan”) for awards granted on or af |
|
| January 19, 2024 |
As filed with the Securities and Exchange Commission on January 19, 2024 S-8 POS As filed with the Securities and Exchange Commission on January 19, 2024 Registration No. |
|
| January 19, 2024 |
2023 Equity Incentive Plan and forms of award agreements thereunder. EX-99.1 Exhibit 99.1 MEDICINOVA, INC. 2023 EQUITY INCENTIVE PLAN MEDICINOVA, INC. 2023 EQUITY INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Board adopted the Plan on April 26, 2023, subject to the approval of the Company’s stockholders. No Awards may be granted prior to the Effective Date. The Plan replaces the Company’s 2013 Equity Incentive Plan (the “Predecessor Plan”) for awards granted on or af |
|
| January 19, 2024 |
As filed with the Securities and Exchange Commission on January 19, 2024 S-8 POS As filed with the Securities and Exchange Commission on January 19, 2024 Registration No. |
|
| January 19, 2024 |
2023 Equity Incentive Plan and forms of award agreements thereunder. EX-99.1 Exhibit 99.1 MEDICINOVA, INC. 2023 EQUITY INCENTIVE PLAN MEDICINOVA, INC. 2023 EQUITY INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Board adopted the Plan on April 26, 2023, subject to the approval of the Company’s stockholders. No Awards may be granted prior to the Effective Date. The Plan replaces the Company’s 2013 Equity Incentive Plan (the “Predecessor Plan”) for awards granted on or af |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K/A Amendment No. |
|
| March 28, 2023 |
Exhibit 10.27 COMPREHENSIVE TERMINATION AGREEMENT This Comprehensive Termination Agreement (the "Agreement") is made as of this 24th day of October, 2022 (the "Effective Date") by and between Kissei Pharmaceutical Co., Ltd., a corporation duly organized and existing under the laws of Japan and having its registered office at 19-48, Yoshino, Matsumoto-City, Nagano-Prefecture 399-8710, Japan ("Kisse |
|
| March 28, 2023 |
Subsidiaries of the Registrant. Exhibit 21 Subsidiaries of the Registrant STATE JURISDICTION MEDICINOVA JAPAN INC. JAPAN AVIGEN, INC DE US, DE CORPORATION MEDICINOVA (EUROPE)LIMITED UK MEDICINOVA EUROPE GmbH GERMANY |
|
| February 16, 2023 |
Exhibit 10.27 COMPREHENSIVE TERMINATION AGREEMENT This Comprehensive Termination Agreement (the "Agreement") is made as of this 24th day of October, 2022 (the "Effective Date") by and between Kissei Pharmaceutical Co., Ltd., a corporation duly organized and existing under the laws of Japan and having its registered office at 19-48, Yoshino, Matsumoto-City, Nagano-Prefecture 399-8710, Japan ("Kisse |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from. |
|
| February 16, 2023 |
Subsidiaries of the Registrant. Exhibit 21 Subsidiaries of the Registrant STATE JURISDICTION MEDICINOVA JAPAN INC. JAPAN AVIGEN, INC DE US, DE CORPORATION MEDICINOVA (EUROPE)LIMITED UK MEDICINOVA EUROPE GmbH GERMANY |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| September 30, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267094 PROSPECTUS SUPPLEMENT (To Prospectus dated September 6, 2022) $64,700,000 Common Stock We are parties to an existing at market issuance sales agreement, or the sales agreement (as amended on August 26, 2022 by Amendment No. 1 to the sales agreement), with B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.), or B. Ri |
|
| September 1, 2022 |
September 1, 2022 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| August 26, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) MediciNova, Inc. |
|
| August 26, 2022 |
Form of Indenture with respect to the Securities. Exhibit 4.5 INDENTURE between MEDICINOVA, INC. as Issuer and [TRUSTEE] as Trustee Dated as of , 20 Providing for the Issuance of Debt Securities in Series MEDICINOVA, INC. Reconciliation and tie between the Trust Indenture Act of 1939 and the Indenture Trust Indenture Act Section Indenture Section Sec. 310(a)(1) 607 (a)(2) 607 (b) 608 Sec. 312(c) 701 Sec. 314(a) 703 (c)(1) 102 (c)(2) 102 (e) 102 S |
|
| August 26, 2022 |
As filed with the Securities and Exchange Commission on August 26, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 26, 2022 Registration No. |
|
| August 26, 2022 |
EX-1.3 2 d398098dex13.htm EX-1.3 Exhibit 1.3 AMENDMENT NO. 1 TO AT MARKET ISSUANCE SALES AGREEMENT August 26, 2022 B. Riley Securities, Inc. 299 Park Avenue, 7th Floor New York, NY 10171 Ladies and Gentlemen: MediciNova, Inc. (the “Company”) and B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.) (the “Agent,”) are parties to that certain At Market Issuance Sales Agreement dated August 23, 201 |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| July 12, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) MEDICINOVA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 58468P206 (CUSIP Number) 3D Invest |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 15, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 13, 2022 |
As filed with the Securities and Exchange Commission on May 13, 2022 As filed with the Securities and Exchange Commission on May 13, 2022 Registration No. |
|
| May 13, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) MediciNova, Inc. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from. |
|
| February 16, 2022 |
EX-4 2 mnov-ex46.htm EX-4.3 Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK General MediciNova, Inc. (“we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended - our common stock, $0.001 par value per share. The following information describes our capital stock, as well as certain provisions of our restated certificate of incorporati |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| August 2, 2021 |
Exhibit 99.1 SERVICES AGREEMENT This Agreement is entered into August 1, 2021 between Signature Analytics LLC (?SA?) and MediciNova, Inc. (?Client?) located at 4275 Executive Square, Suite 300, La Jolla, CA 92037. 1. Services. During the term of this Agreement, SA will provide financial and accounting services (?Services?) as agreed from time to time by Client and SA. All such Services shall be pe |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2021 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 23, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2021 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 23, 2021 |
LEASE THE IRVINE COMPANY LLC MEDICINOVA, INC. Exhibit 99.1 LEASE BETWEEN THE IRVINE COMPANY LLC AND MEDICINOVA, INC. LEASE (Short Form) THIS LEASE is made as of July 20, 2021 , by and between THE IRVINE COMPANY LLC, a Delaware limited liability company, hereafter called ?Landlord,? and MEDICINOVA, INC., a Delaware corporation, hereafter called ?Tenant.? ARTICLE 1. BASIC LEASE PROVISIONS Each reference in this Lease to the ?Basic Lease Provisi |
|
| June 17, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from. |
|
| February 19, 2021 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK General MediciNova, Inc. (?we,? ?us,? and ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended - our common stock, $0.001 par value per share. The following information describes our capital stock, as well as certain provisions of our restated certificate of incorporation, as amended, and amended |
|
| February 12, 2021 |
3,656,307 Shares of Common Stock to be Offered by the Selling Stockholder 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration File No. 333-252592 PROSPECTUS 3,656,307 Shares of Common Stock to be Offered by the Selling Stockholder This prospectus relates to the resale or other disposition from time to time of up to an aggregate of 3,656,307 shares of common stock, par value of $0.001 per share of MediciNova, Inc. by the selling stockholder identified i |
|
| February 8, 2021 |
February 8, 2021 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N. |
|
| February 1, 2021 |
MediciNova Announces Closing of US$20 Million Private Placement Transaction EX-99.1 Exhibit 99.1 MediciNova Announces Closing of US$20 Million Private Placement Transaction LA JOLLA, Calif., January 31, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the closing of the previously announced private placement transacti |
|
| February 1, 2021 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File |
|
| January 29, 2021 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on January 29, 2021 Registration No. |
|
| January 21, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) MEDICINOVA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 58468P206 (CUSIP Number) 3D Investment Partners Pte. |
|
| January 21, 2021 |
EX-99.3 2 exhibit3.htm JOINT FILING AGREEMENT EXHIBIT 3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of MediciNova, Inc. and further a |
|
| January 12, 2021 |
EX-99.1 Exhibit 99.1 MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners LA JOLLA, Calif., January 11, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has entered into a Sec |
|
| January 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File |
|
| January 12, 2021 |
Securities Purchase Agreement, dated January 11, 2021, between the Company and the Investor. EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 11, 2021, between MediciNova, Inc., a Delaware corporation (the “Company”) and 3D Opportunity Master Fund, a Cayman Islands exempt company (the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to |
|
| January 12, 2021 |
Shareholder Rights Agreement, dated January 11, 2021, between the Company and the Investor. EX-10.2 Exhibit 10.2 SHAREHOLDER RIGHTS AGREEMENT THIS SHAREHOLDER RIGHTS AGREEMENT (this “Agreement”), is made and entered into as of January 11, 2021 by and among MediciNova, Inc., a Delaware corporation, (the “Company”) and 3D Opportunity Master Fund, a Cayman Islands exempt company (the “Shareholder”). RECITALS WHEREAS, the Company and the Shareholder are entering into a certain Securities Pur |
|
| October 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| October 21, 2020 |
MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair EX-99.1 Exhibit 99.1 MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair LA JOLLA, Calif., October 21, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Ms. Carolyn Beaver to its Board o |
|
| October 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2020 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File |
|
| July 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| June 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 17, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2020 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2020 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 13, 2020 |
MNOV / Medicinova, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from. |
|
| October 28, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2019 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission F |
|
| October 25, 2019 |
MNOV / Medicinova, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| October 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2019 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File |
|
| August 23, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2019 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 23, 2019 |
EX-10.1 Exhibit 10.1 MEDICINOVA, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement August 23, 2019 B. Riley FBR, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: MediciNova, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with B. Riley FBR, Inc. (the “Agent”), as follows: 1. Issuance and Sale of Share |
|
| August 23, 2019 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233201 PROSPECTUS SUPPLEMENT (to the Prospectus dated August 22, 2019) $75,000,000 Common Stock We have entered into an at market issuance sales agreement, or sales agreement, with B. Riley FBR, Inc., or B. Riley FBR, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospe |
|
| August 20, 2019 |
MNOV / Medicinova, Inc. CORRESP - - CORRESP August 20, 2019 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| August 9, 2019 |
Form of Indenture with respect to the Securities. EX-4.5 Exhibit 4.5 INDENTURE between MEDICINOVA, INC. as Issuer and [TRUSTEE] as Trustee Dated as of , 20 Providing for the Issuance of Debt Securities in Series MEDICINOVA, INC. Reconciliation and tie between the Trust Indenture Act of 1939 and the Indenture Trust Indenture Act Section Indenture Section Sec. 310(a)(1) 607 (a)(2) 607 (b) 608 Sec. 312(c) 701 Sec. 314(a) 703 (a)(4) 1004 (c)(1) 102 ( |
|
| August 9, 2019 |
MNOV / Medicinova, Inc. S-3 - - S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 9, 2019 Registration No. |
|
| July 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2019 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 25, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2019 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File |
|
| July 25, 2019 |
MediciNova Appoints Kazuko Matsuda to its Board of Directors EX-99.1 Exhibit 99.1 MediciNova Appoints Kazuko Matsuda to its Board of Directors LA JOLLA, Calif., July 24, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Dr. Kazuko Matsuda to its Board of Directors. Dr. Matsuda receive |
|
| July 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| June 21, 2019 |
2013 Equity Incentive Plan, as amended. EX-99.1 Exhibit 99.1 MEDICINOVA, INC. 2013 EQUITY INCENTIVE PLAN (as amended by the Board of Directors March 14, 2019) 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the MediciNova, Inc. Amended and Restated 2004 Stock Incentive Plan (the “Prior Plan”). Following the Effective Date, no additional stock awards may be granted |
|
| June 21, 2019 |
MNOV / Medicinova, Inc. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on June 21, 2019 Registration No. |
|
| June 11, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2019 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 1, 2019 |
MNOV / Medicinova, Inc. DEFA14A DEFA14A DEFA14A 1 mnov-defa14a20190412.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 26, 2019 |
DEF 14A 1 mnov-def14a20181231.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2019 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 25, 2019 |
EX-3.1 EXHIBIT 3.1 FORM OF AMENDED AND RESTATED BYLAWS OF THE REGISTRANT MEDICINOVA, INC. (a Delaware corporation) TABLE OF CONTENTS Page Article 1 Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article 2 Meeting of Stockholders 1 2.1 Place of Meeting 1 2.2 Annual Meeting 1 2.3 Special Meetings 3 2.4 Notice of Meetings 3 2.5 List of Stockholders 3 2.6 Organization and Conduct of Business 3 |
|
| April 25, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2019 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| March 12, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2019 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2019 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File |
|
| February 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from. |
|
| October 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2018 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File |
|
| October 25, 2018 |
MNOV / Medicinova, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| July 24, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2018 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 23, 2018 |
MNOV / Medicinova, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| June 11, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2018 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 5, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2018 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission |
|
| May 17, 2018 |
MNOV / Medicinova, Inc. / Satomi Hajime - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* MEDICINOVA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 58468P206 (CUS |
|
| May 9, 2018 |
MNOV / Medicinova, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| April 26, 2018 |
MNOV / Medicinova, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2018 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 25, 2018 |
MNOV / Medicinova, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| February 21, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2018 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2018 |
mnov-8k20180214.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2018 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporati |
|
| February 13, 2018 |
MNOV / Medicinova, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from. |
|
| February 8, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2018 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission F |
|
| February 8, 2018 |
MediciNova Announces Pricing of Underwritten Public Offering of Common Stock EX-99.2 Exhibit 99.2 MediciNova Announces Pricing of Underwritten Public Offering of Common Stock LA JOLLA, Calif., February 7, 2018 ? MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced today the pricing of an underwritten public offering of 4,419,890 shares of its common st |
|
| February 8, 2018 |
MediciNova Announces Proposed Underwritten Public Offering of Common Stock EX-99.1 Exhibit 99.1 MediciNova Announces Proposed Underwritten Public Offering of Common Stock LA JOLLA, Calif., February 7, 2018 ? MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced today that it intends to offer shares of its common stock in an underwritten public offerin |
|
| February 8, 2018 |
EX-1.1 Exhibit 1.1 Execution Version MEDICINOVA, INC. 4,419,890 Shares of Common Stock UNDERWRITING AGREEMENT February 7, 2018 Ladenburg Thalmann & Co. Inc. As Representative of the several underwriters listed on Schedule I hereto 277 Park Avenue 26th Floor New York, NY 10172 Ladies and Gentlemen: MEDICINOVA, INC., a Delaware corporation (the ?Company?), proposes to issue and sell to Ladenburg Tha |
|
| February 8, 2018 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-220593 PROSPECTUS SUPPLEMENT (To Prospectus dated October 2, 2017) 4,419,890 shares MediciNova, Inc. Common Stock We are offering 4,419,890 shares of our common stock. Our common stock is traded on the Nasdaq Global Market under the symbol ?MNOV? and on the Jasdaq Market of the Tokyo Securities Exchange under the code ?4 |
|
| February 7, 2018 |
SUBJECT TO COMPLETION, DATED FEBRUARY 7, 2018 PRELIMINARY PROSPECTUS SUPPLEMENT 424(b)(5) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-220593 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not offers to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is n |
|
| November 13, 2017 |
POWER OF ATTORNEY For Executing Section 16 Forms, Form 144 and Schedules 13D or 13G Exhibit 24 POWER OF ATTORNEY For Executing Section 16 Forms, Form 144 and Schedules 13D or 13G Know all by these presents that the undersigned hereby constitutes and appoints Yuichi Iwaki as the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of MediciNova, Inc. |
|
| November 13, 2017 |
mnov-8k20171113.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2017 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporatio |
|
| November 13, 2017 |
MediciNova Appoints Hideki Nagao to its Board of Directors mnov-ex9917.htm MediciNova Appoints Hideki Nagao to its Board of Directors LA JOLLA, Calif., November 09, 2017 (GLOBE NEWSWIRE) - MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Mr. Hideki Nagao to its Board of Directors. Mr. Nagao complements th |
|
| October 30, 2017 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2017 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commiss |
|
| October 30, 2017 |
MediciNova Announces the Presentation of Additional Positive Exhibit 99.1 Exhibit 99.1 MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS: Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability Profile LA JOLLA, Calif., October 30, 2017 (GLOBE NEWSWIRE) ? MediciNova, Inc., a biopharmaceutical compan |
|
| October 24, 2017 |
mnov-8k20170930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2017 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporatio |
|
| October 23, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| September 27, 2017 |
CORRESP September 27, 2017 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| September 22, 2017 |
Statement Regarding Computation of Ratio of Earnings to Fixed Charges and Preferred Stock Dividends Exhibit 12.1 Statement Regarding Computation of Ratio of Earnings to Fixed Charges and Preferred Stock Dividends Year Ended December 31, Six Months Ended June 30, 2017 (in thousands) 2012 2013 2014 2015 2016 Earnings: Loss before income taxes $ (10,950 ) $ (4,024 ) $ (9,199 ) $ (8,838 ) $ (10,862 ) $ (5,799 ) Add: Fixed charges ? ? 1 1 1 ? Total Earnings $ (10,950 ) $ (4,024 ) $ (9,198 ) $ (8,837 |
|
| September 22, 2017 |
As filed with the Securities and Exchange Commission on September 22, 2017 As filed with the Securities and Exchange Commission on September 22, 2017 Registration No. |
|
| September 22, 2017 |
Form of Indenture with respect to the Securities. Exhibit 4.5 INDENTURE between MEDICINOVA, INC. as Issuer and [TRUSTEE] as Trustee Dated as of , 20 Providing for the Issuance of Debt Securities in Series MEDICINOVA, INC. Reconciliation and tie between the Trust Indenture Act of 1939 and the Indenture Trust Indenture Act Section Indenture Section Sec. 310(a)(1) 607 (a)(2) 607 (b) 608 Sec. 312(c) 701 Sec. 314(a) 703 (a)(4) 1004 (c)(1) 102 (c)(2) 1 |
|
| September 7, 2017 |
EX-10.1 Exhibit 10.1 SUBLEASE AGREEMENT 1. Parties. This Sublease Agreement (?Sublease?), is made and executed as of August 31, 2017, by and between Cardinal Health 127 Inc., a Kansas Corporation (?Cardinal?) and MediciNova, Inc. a Delaware corporation (?Sublessee?). 2. Premises. Cardinal subleases to Sublessee and Sublessee subleases from Cardinal the Premises. ?Premises? means the real property |
|
| September 7, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2017 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commissi |
|
| July 27, 2017 |
8-K 1 mnov-8k20170630.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2017 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incor |
|
| July 26, 2017 |
mnov-s8.htm As filed with the Securities and Exchange Commission on July 26, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 33-0927979 (State or other jurisdiction of (I.R.S. Employer incorporation or o |
|
| July 26, 2017 |
MediciNova, Inc. 2013 EQUITY INCENTIVE PLAN (as amended by the Board of Directors April 6, 2017) EX-99.1 5 mnov-ex9916.htm EX-99.1 Exhibit 99.1 MediciNova, Inc. 2013 EQUITY INCENTIVE PLAN (as amended by the Board of Directors April 6, 2017) 1.General. (a)Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the MediciNova, Inc. Amended and Restated 2004 Stock Incentive Plan (the “Prior Plan”). Following the Effective Date, no additional stoc |
|
| July 26, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| July 26, 2017 |
Exhibit 10.1 MediciNova, Inc. 2013 EQUITY INCENTIVE PLAN (as amended by the Board of Directors April 6, 2017) 1.General. (a)Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the MediciNova, Inc. Amended and Restated 2004 Stock Incentive Plan (the “Prior Plan”). Following the Effective Date, no additional stock awards may be granted under the |
|
| June 14, 2017 |
MNOV / Medicinova, Inc. / Kissei Pharmaceutical Co., Ltd. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* MediciNova, Inc. (Name of Issuer) Common Stock, par value $0.001 per Share (Title of Class of Securities) 58468P206 (CUSIP Number) Hiroe Satou Member of the Board and Senior Director, Corporate Finance & Management KISSEI PHARMACEUTICAL CO., LTD |
|
| June 12, 2017 |
Submission of Matters to a Vote of Security Holders mnov-8k20170608.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2017 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) ( |
|
| April 27, 2017 |
DEF 14A 1 mnov-def14a20170608.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 27, 2017 |
mnov-8k20170427.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2017 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) |
|
| April 26, 2017 |
Medicinova 10-Q (Quarterly Report) mnov-10q20170331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2017 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001 |
|
| February 15, 2017 |
mnov-8k20170215.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2017 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation) 001-33185 (Commis |
|
| February 14, 2017 |
Medicinova 10-K (Annual Report) mnov-10k20161231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from. to Commission file number: 001- |
|
| December 9, 2016 |
MEDICINOVA, INC. 869,047 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration File No. 333-214830 PROSPECTUS MEDICINOVA, INC. 869,047 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants The selling stockholders named in this prospectus are offering up to 869,047 shares of our common stock they may acquire upon the exercise of outstanding warrants. We issued an aggregate of two warrants ( |
|
| November 29, 2016 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on November 29, 2016 Registration No. |
|
| November 10, 2016 |
EX-99.1 Exhibit 99.1 Corporate Presentation November 2016 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding MediciNova?s clinical trials supporting the |
|
| November 10, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2016 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commis |
|
| October 26, 2016 |
mnov-8k20160930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2016 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation) 001-33185 (Commiss |
|
| October 25, 2016 |
Medicinova 10-Q (Quarterly Report) mnov-10q20160930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: |
|
| September 16, 2016 |
$29,967,000 MEDICINOVA, INC. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-208274 PROSPECTUS SUPPLEMENT (to the Prospectus dated August 29, 2016) $29,967,000 MEDICINOVA, INC. Common Stock We are offering up to an aggregate of $29,967,000 of shares of our common stock, par value $0.001 per share, pursuant to our sales agreement with MLV & Co. LLC (?MLV?), dated May 22, 2015, as amended on Septem |
|
| September 16, 2016 |
EX-10.1 Exhibit 10.1 AMENDMENT NO. 1 TO AT-THE-MARKET ISSUANCE SALES AGREEMENT September 16, 2016 Ladies and Gentlemen: MediciNova, Inc. (the ?Company?), and MLV & Co. LLC (?MLV?) , are parties to that certain At-the-Market Issuance Sales Agreement dated May 22, 2015 (the ?Original Agreement?). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreem |
|
| September 16, 2016 |
Medicinova 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2016 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission |
|
| August 25, 2016 |
CORRESP August 25, 2016 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| August 25, 2016 |
CORRESP August 25, 2016 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| August 24, 2016 |
EX-12.1 Exhibit 12.1 Computation of Ratio of Earnings to Fixed Charges and Preferred Stock Dividends Year Ended December 31, Six Months Ended June 30, 2016 (in thousands) 2011 2012 2013 2014 2015 Earnings: Loss before income taxes $ (17,723 ) $ (10,950 ) $ (4,024 ) $ (9,199 ) $ (8,838 ) $ (6,578 ) Add: Fixed charges 1,595 ? ? 1 1 ? Total Earnings $ (16,128 ) $ (10,950 ) $ (4,024 ) $ (9,198 ) $ (8, |
|
| August 24, 2016 |
EX-12.1 Exhibit 12.1 Computation of Ratio of Earnings to Fixed Charges and Preferred Stock Dividends Year Ended December 31, Six Months Ended June 30, 2016 (in thousands) 2011 2012 2013 2014 2015 Earnings: Loss before income taxes $ (17,723 ) $ (10,950 ) $ (4,024 ) $ (9,199 ) $ (8,838 ) $ (6,578 ) Add: Fixed charges 1,595 ? ? 1 1 ? Total Earnings $ (16,128 ) $ (10,950 ) $ (4,024 ) $ (9,198 ) $ (8, |
|
| August 24, 2016 |
S-3/A Table of Contents As filed with the Securities and Exchange Commission on August 24, 2016 Registration No. |
|
| August 24, 2016 |
S-3/A Table of Contents As filed with the Securities and Exchange Commission on August 24, 2016 Registration No. |
|
| July 27, 2016 |
8-K 1 mnov-8k20160726.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2016 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation) 001-33185 ( |
|
| July 26, 2016 |
Medicinova 10-Q (Quarterly Report) mnov-10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001- |
|
| June 13, 2016 |
Submission of Matters to a Vote of Security Holders mnov-8k20160609.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2016 MEDICINOVA, INC. (Exact name of Registrant as Specified in Its Charter) DELAWARE 001-33185 33-0927979 (State or Other Jurisdiction of Incorporation) ( |
|
| May 17, 2016 |
Schedule 13D (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* MediciNova, Inc. (Name of Issuer) Common Stock, par value $0.001 per Share (Title of Class of Securities) 58468P206 (CUSIP Number) Hiroe Satou Member of the Board and Senior Director, Corporate Finance & Management KISSEI P |
|
| April 28, 2016 |
8-K 1 mnov-8k20160428.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2016 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation) 001-33185 |
|
| April 27, 2016 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 27, 2016 |
MediciNova 10-Q (Quarterly Report) mnov-10q20160331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001 |
|
| March 31, 2016 |
EX-10.1 2 d171332dex101.htm EX-10.1 Exhibit 10.1 SERVICES AGREEMENT This Agreement is entered into March 31, 2016 between Signature Analytics San Diego LLC (“SA”) and MediciNova, Inc. (“Client”). 1. Services. During the term of this Agreement, SA will provide financial and accounting services as agreed from time to time by Client and SA (“Services”). The Services shall initially include Service by |
|
| March 31, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2016 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commissio |
|
| March 31, 2016 |
POWER OF ATTORNEY For Executing Section 16 Forms, Form 144 and Schedules 13D or 13G Exhibit 24 POWER OF ATTORNEY For Executing Section 16 Forms, Form 144 and Schedules 13D or 13G Know all by these presents that the undersigned hereby constitutes and appoints Yui Iwaki as the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of MediciNova, Inc. |
|
| February 26, 2016 |
MediciNova 8-K (Current Report/Significant Event) mnov-8k20160226.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2016 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation) 001-33185 (Commis |
|
| February 25, 2016 |
MediciNova 10-K (Annual Report) mnov-10k20151231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3 |
|
| February 12, 2016 |
EX-99.1 2 d124261dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D relating to the Common Stock of Medicinova, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13D will, unless written notice to the contrary is delivered as described below, be jointly filed on |
|
| February 12, 2016 |
MNOV / Medicinova, Inc. / ESSEX WOODLANDS HEALTH VENTURES FUND VI L P - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Medicinova, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 58468P206 (CUSIP Number) Martin P. Sutter Essex Woodlands Health Ventures Fund VI, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Texas 7 |
|
| December 18, 2015 |
S-3/A Table of Contents As filed with the Securities and Exchange Commission on December 18, 2015 Registration No. |
|
| December 1, 2015 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on December 1, 2015 Registration No. |
|
| December 1, 2015 |
EX-4.1 2 d68859dex41.htm EX-4.1 Exhibit 4.1 MEDICINOVA, INC. TO [ ] Trustee Indenture Dated as of , 20 MediciNova, Inc. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of , 20 Trust Indenture Act Section Indenture Sections § 310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608 610 § 311(a) 613(a) (b) 613(b) (b)(2) 703(a)(2) 703( |
|
| October 30, 2015 |
Medicinova 8-K (Current Report/Significant Event) mnov-8k20151030.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation) 001-33185 (Commiss |
|
| October 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 10-Q 1 mnov-10q20150930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission |
|
| September 25, 2015 |
Medicinova FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commi |
|
| September 25, 2015 |
EX-99.1 ? MediciNova, Inc. 2015 Developing Novel Therapeutics for the Treatment of Serious Diseases with Unmet Medical Needs Exhibit 99.1 ? MediciNova, Inc. 2015 Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statem |
|
| September 1, 2015 |
Medicinova FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commis |
|
| August 25, 2015 |
MediciNova Announces Closing of Underwritten Public Offering of Common Stock EX-99.1 2 d45864dex991.htm EX-99.1 Exhibit 99.1 MediciNova Announces Closing of Underwritten Public Offering of Common Stock LA JOLLA, Calif., August 24, 2015 — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced today closing of the previously announced underwritten public o |
|
| August 25, 2015 |
Medicinova FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commissi |
|
| August 19, 2015 |
MediciNova Announces Pricing of Underwritten Public Offering of Common Stock EX-99.2 5 d82697dex992.htm EX-99.2 Exhibit 99.2 MediciNova Announces Pricing of Underwritten Public Offering of Common Stock LA JOLLA, Calif., August 18, 2015 — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced today the pricing of an underwritten public offering of 5,000,0 |
|
| August 19, 2015 |
MEDICINOVA, INC. 5,000,000 Shares of Common Stock UNDERWRITING AGREEMENT EX-1.1 2 d82697dex11.htm EX-1.1 Exhibit 1.1 MEDICINOVA, INC. 5,000,000 Shares of Common Stock UNDERWRITING AGREEMENT August 18, 2015 Ladenburg Thalmann & Co. Inc. As Representative of the several underwriters listed on Schedule I hereto 570 Lexington Avenue 11th Floor New York, NY 10022 Ladies and Gentlemen: MEDICINOVA, INC., a Delaware corporation (the “Company”), proposes to issue and sell to La |
|
| August 19, 2015 |
MediciNova Announces Proposed Underwritten Public Offering of Common Stock EX-99.1 4 d82697dex991.htm EX-99.1 Exhibit 99.1 MediciNova Announces Proposed Underwritten Public Offering of Common Stock LA JOLLA, Calif., August 18, 2015 — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced today that it intends to offer shares of its common stock in an u |
|
| August 19, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d82697d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorpora |
|
| August 19, 2015 |
MEDICINOVA, INC. 5,000,000 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-185022 PROSPECTUS SUPPLEMENT (to the Prospectus dated December 3, 2012) MEDICINOVA, INC. 5,000,000 Shares of Common Stock We are offering 5,000,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the symbol ?MNOV? and on the Jasdaq Market of the Tokyo Securities Exchange under the |
|
| August 18, 2015 |
SUBJECT TO COMPLETION, DATED AUGUST 18, 2015 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-185022 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell nor do they seek an offer to buy these securities in any jurisdiction where the offer or sale |
|
| July 31, 2015 |
mnov-8k20150731.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation) 001-33185 (Commission |
|
| July 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| July 2, 2015 |
EX-16.1 Exhibit 16.1 July 2, 2015 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 (a) of Form 8-K dated July 2, 2015, of MediciNova, Inc. and are in agreement with the statements contained in the second sentence of paragraph 1 and the entirety of paragraphs 2, 3 and 4 of Item 4.01 (a), Changes in Registrant?s Certifying Accoun |
|
| July 2, 2015 |
Medicinova FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission |
|
| June 15, 2015 |
Submission of Matters to a Vote of Security Holders 8-K 1 d941959d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incor |
|
| May 22, 2015 |
Medicinova FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission |
|
| May 22, 2015 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-185022 PROSPECTUS SUPPLEMENT (to the Prospectus dated December 3, 2012) MEDICINOVA, INC. $30,000,000 Common Stock We have entered into an at-the-market issuance sales agreement, or sales agreement, with MLV & Co. LLC, or MLV, relating to shares of our common stock offered by this prospectus supplement and the accompanyin |
|
| May 22, 2015 |
EX-10.1 Exhibit 10.1 MEDICINOVA, INC. Common Stock (par value $0.001 per share) At-the-Market Issuance Sales Agreement May 22, 2015 MLV & Co. LLC 1301 Avenue of the Americas 43rd Floor New York, New York 10019 Ladies and Gentlemen: MediciNova, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?), with MLV & Co. LLC (?MLV?), as follows: 1. Issuance and Sale of Sha |
|
| May 12, 2015 |
Medicinova FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| April 29, 2015 |
DEF 14A 1 d896346ddef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as p |
|
| April 29, 2015 |
8-K 1 d916041d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of inco |
|
| April 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 3, 2015 |
EX-10.1 Exhibit 10.1 ENGAGEMENT AGREEMENT April 3, 2015 Dr. Yuichi Iwaki Chief Executive Officer MediciNova, Inc. 4275 Executive Square, Suite 650 San Diego, CA 92037 Dear Dr. Iwaki, This agreement (together with all attachments hereto, the ?Agreement?) is made effective April 3, 2015 and confirms the engagement of van den Boom & Associates, LLC (?we? or ?van den Boom?) to assist MediciNova, Inc. |
|
| March 13, 2015 |
Medicinova 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2015 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33185 MEDICINOVA, INC. |
|
| November 14, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2014 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission |
|
| November 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| October 17, 2014 |
EX-99.1 © MediciNova, Inc. 2014 Developing Novel Therapeutics for the Treatment of Serious Diseases with Unmet Medical Needs Exhibit 99.1 © MediciNova, Inc. 2014 © MediciNova, Inc. 2014 Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Thes |
|
| October 17, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2014 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commiss |
|
| August 19, 2014 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2014 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commissi |
|
| August 19, 2014 |
EX-99.1 Exhibit 99.1 MediciNova Announces Positive Interim Results of Phase 2a Study of MN-166 (ibudilast) in Opioid Dependence LA JOLLA, Calif., August 18, 2014 (GLOBE NEWSWIRE) — MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Trading Symbol: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive interim results of a |
|
| August 14, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2014 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 13, 2014 |
EX-10.4 4 d745670dex104.htm EX-10.4 Exhibit 10.4 SEVERANCE PROTECTION AGREEMENT SEVERANCE PROTECTION AGREEMENT, dated July 14, 2014, by and between MediciNova, Inc., a Delaware corporation (the “Company”), and Dr. Kazuko Matsuda (the “Executive”). PURPOSE The Board of Directors of the Company (the “Board”) recognizes that the possibility of a Change in Control (as hereinafter defined) of the Compa |
|
| August 13, 2014 |
Exhibit 10.5 SEVERANCE PROTECTION AGREEMENT SEVERANCE PROTECTION AGREEMENT, dated July 14, 2014, by and between MediciNova, Inc., a Delaware corporation (the ?Company?), and Geoffrey O?Brien (the ?Executive?). PURPOSE The Board of Directors of the Company (the ?Board?) recognizes that the possibility of a Change in Control (as hereinafter defined) of the Company exists and that the threat or occur |
|
| August 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-33185 MEDICINOVA, INC. |
|
| August 13, 2014 |
Exhibit 10.3 SEVERANCE PROTECTION AGREEMENT SEVERANCE PROTECTION AGREEMENT, dated July 14, 2014, by and between MediciNova, Inc., a Delaware corporation (the “Company”), and Masatsune Okajima (the “Executive”). PURPOSE The Board of Directors of the Company (the “Board”) recognizes that the possibility of a Change in Control (as hereinafter defined) of the Company exists and that the threat or occu |
|
| August 13, 2014 |
Exhibit 10.2 SEVERANCE PROTECTION AGREEMENT SEVERANCE PROTECTION AGREEMENT, dated July 14, 2014, by and between MediciNova, Inc., a Delaware corporation (the ?Company?), and Dr. Yuichi Iwaki (the ?Executive?). PURPOSE The Board of Directors of the Company (the ?Board?) recognizes that the possibility of a Change in Control (as hereinafter defined) of the Company exists and that the threat or occur |
|
| July 11, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2014 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) Delaware 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission |
|
| July 11, 2014 |
SEVERANCE PROTECTION AGREEMENT EX-10.1 2 d754516dex101.htm EX-10.1 Exhibit 10.1 SEVERANCE PROTECTION AGREEMENT SEVERANCE PROTECTION AGREEMENT, dated [ ], 2014, by and between MediciNova, Inc., a Delaware corporation (the “Company”), and (the “Executive”). PURPOSE The Board of Directors of the Company (the “Board”) recognizes that the possibility of a Change in Control (as hereinafter defined) of the Company exists and that the |
|
| June 17, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2014 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission |
